Skip to content
thestock.space

On 6 Nov 2026, Alembic Pharmaceuticals was priced at ₹965.15, or 22.5× trailing earnings, against an industry P/E of 28.7×. Sales and net profit grew 9.5% and 25% a year over 3 years; its ROCE of 13% is the second-lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers. Debt is 0.26× equity, and its dividend yield is 1.2%. It is a small-cap company with a market cap of ₹18,971 Cr, ranked 22nd of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 7.0% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year
Open
₹894.80
Day high
₹985.00
Day low
₹890.00
Prev. close
₹893.50
Volume
23.7 L

Health check

3 good · 2 fair · 1 to check
  • ReturnsBehind

    −7.0% over a year, better than 0 of 7 peers.

  • Price tagCheaper

    P/E 22.5 vs industry 28.7.

  • GrowthSteady

    Sales +9.5%, profit +25.4% a year over 3 years.

  • ProfitabilityAverage

    ROCE 12.8% vs peer median 17.9%.

  • Balance sheetSolid

    Debt 0.26× equity, interest covered 8.4×, Piotroski 7 of 9.

  • Red flagsNone found

    No warning signs in the headline numbers.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹18,971 Cr, #22 of 154 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Sep 2026: sales ₹8,494 Cr · profit ₹844 Cr
Market cap
₹18,971 Cr
Small cap
P/E
22.5
Industry 28.7
Price to book
3.19
Peers 4.99
Dividend yield
1.24%
ROE
14.9%
Peers 14.7%
ROCE
12.8%
Peers 17.9%
Debt to equity
0.26
Debt ₹1,547 Cr
EPS (TTM)
₹42.93
Face value ₹2
OPM (TTM)
16.7%
Net margin 9.9%
Sales growth
+37.1%
Latest quarter vs a year ago
Profit growth
+81.4%
Latest quarter vs a year ago
Price to sales
2.23
EV/EBITDA 14.3

Strengths and risks

Strengths

  • Quarterly profit up 81.4% on a year ago.
  • Quarterly sales up 37.1% on a year ago.
  • Positive operating cash flow in each of the last 4 years.

No obvious red flags in the headline numbers.

Derived automatically from reported figures. Not a recommendation.

About Alembic Pharmaceuticals

Alembic Pharmaceuticals Limited, an integrated pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical products in India and internationally. The company provides products in various therapeutic areas, such as cardiology, orthopaedics, anti-diabetic, ophthalmology, gynaecology, nephrology, gastrology, urology, dermatology, anti-infective, cold and cough, and animal health; generics formulations in oral solids, oncology oral…

Headquarters
Vadodara
Employees
17,244
Sector
Healthcare
ISIN
INE901L01018
Website
alembicpharmaceuticals.com

Price range

52 weeks

₹635.80₹985.00

Today

₹890.00₹985.00
Avg volume (3M)
2.8 L
1-year return
minus 7.0%
From 52-week high
minus 2.0%

Analyst consensus

10 analysts
BuyMean target ₹978.30 plus 1.4%

Target range, with today’s price

Low ₹840.00High ₹1,132.00

Consensus from Yahoo Finance. Not a recommendation.

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.86%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.29%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.80%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.58%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.92%minus 6.6%
APLLTDAlembic Pharmaceuticals965.15plus 8.02%18,97122.53.1912.8%12.4%15.0%9.5%25.4%1.24%minus 7.0%
Median of 7 peers–0.51%1,26,43340.94.9917.9%14.7%28.2%11.0%11.5%0.58%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Dec 25Mar 26Jun 26Sep 26
1,7111,8761,8482,1502,603
1,4291,5831,6201,8182,040
281294228332563
16.4%15.6%12.3%15.4%21.6%
613.726.615.313.7
23.523.322.627.638.3
73.880.188.697.7101
–−42.2−24.8––
190162119222438
19.2%18.3%−69.9%22.3%23.8%
154133203173335
7.856.7610.318.8017.05

Sep 25 not reported by the data source.

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+9.5%
Profit CAGR 3Y
+25.4%
EPS CAGR 3Y
+25.4%
ROE
14.9%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
5,5006,1126,5407,213
–+11.1%+7.0%+10.3%
4,7805,1765,5266,090
7209361,0141,122
13.1%15.3%15.5%15.6%
−30.419.338.151.7
50.256.278.893.6
275273279319
−8.95.212.8−68.1
355632707694
3.6%2.5%17.7%3.3%
342616583675
–+80.1%minus 5.3%+15.7%
17.4031.3329.6834.33

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
39.339.339.339.3
4,3314,7795,1525,636
7225131,2581,430
1,0901,1141,3251,658
6,1836,4467,7738,763
3,0003,0713,3923,493
601524868649
71.268.6102113
75.512083.5196
2,4352,6613,3284,311
6,1836,4467,7738,763

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
72480388783
−448−321−568−506
−262−438444−164
14.444.7−36.7113
−443−327−564−495
281476−476288
−197−157−216−216

Shareholding pattern

Source: NSE filings

NSE hasn’t returned a shareholding pattern for this company. Institutions hold about 16.6% (Yahoo estimate).

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you